Item(by='Balgair', descendants=None, kids=[24806555], score=None, time=1602890214, title=None, item_type='comment', url=None, parent=24802146, text='&quot;It looks like there is no case at all to be made for some of these therapies, and for remdesivir, it looks like the argument now is “Does it help a bit or just not at all?” The only thing that I’ve seen that really seems to be making a big difference now is dexamethasone, and we may soon (I hope) be adding the monoclonal antibodies to that list. The SOLIDARITY enrollment is still moving along at 2000 patients&#x2F;month, and will be looking at these and other newer ideas as it continues. And that means abandoning the older ideas, because – as we’re finding out – they’re not much help. It’s time to move on.&quot;<p>Just so everyone knows, this is the same guy that writes the &#x27;Things I Won&#x27;t Work With&quot; blog. It&#x27;s all about insane chemical compounds and is <i>very much</i> one of the best blogs ever written.<p><a href="https:&#x2F;&#x2F;blogs.sciencemag.org&#x2F;pipeline&#x2F;?s=things+I+won%27t+work+with" rel="nofollow">https:&#x2F;&#x2F;blogs.sciencemag.org&#x2F;pipeline&#x2F;?s=things+I+won%27t+wo...</a>')